Skip to main
RIGL
RIGL

Rigel Pharmaceuticals (RIGL) Stock Forecast & Price Target

Rigel Pharmaceuticals (RIGL) Analyst Ratings

Based on 11 analyst ratings
Buy
Strong Buy 36%
Buy 18%
Hold 45%
Sell 0%
Strong Sell 0%

Bulls say

Rigel Pharmaceuticals Inc. has demonstrated a notable increase in product sales across its portfolio, with Tavalisse rising 18% to $31 million, contributing to an overall upsurge in revenues, driven by stronger-than-expected net product sales and increased contract revenues from collaborations. The company achieved a pivotal milestone by reporting positive net income for FY2024, indicating a critical advancement towards sustained profitability and healthy cash flow, complemented by a substantial cash position of $77.3 million at year-end. Looking ahead, Rigel plans to expand its commercial efforts and broaden access to its therapies internationally, while also progressing in clinical trials that hold potential to address unmet medical needs, thereby enhancing the overall outlook for the company's financial performance.

Bears say

The negative outlook on Rigel Pharmaceuticals's stock stems from the potential for ongoing or future clinical trials to fail, which could lead to significant downward selling pressure, particularly if the stock trades near or below the company's cash position. Additionally, the company's ability to secure adequate funding for drug development remains uncertain, and failed or inconclusive trial outcomes could impede progress, further affecting financial stability. Moreover, the limited response depth noted in the swimmer's plot raises concerns regarding the clinical impact of its lead investigational drugs, including R289, compounding the uncertainty surrounding Rigel's future financial performance.

Rigel Pharmaceuticals (RIGL) has been analyzed by 11 analysts, with a consensus rating of Buy. 36% of analysts recommend a Strong Buy, 18% recommend Buy, 45% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Rigel Pharmaceuticals and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Rigel Pharmaceuticals (RIGL) Forecast

Analysts have given Rigel Pharmaceuticals (RIGL) a Buy based on their latest research and market trends.

According to 11 analysts, Rigel Pharmaceuticals (RIGL) has a Buy consensus rating as of Jul 25, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $20.36, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $20.36, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Rigel Pharmaceuticals (RIGL)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.